2023 World Conference on Lung Cancer (Posters)-EP11.01. Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-L1 Expression

EP11.01. Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-L1 Expression - PDF(Slides)

Back to course

Pdf Summary

A low neutrophil-to-lymphocyte ratio (NLR) can predict overall survival benefits in advanced non-small cell lung cancer (NSCLC) patients with low PD-L1 expression who are receiving chemoimmunotherapy, according to a study conducted by researchers at the National Cheng Kung University Hospital in Taiwan. Combination therapy with chemotherapy and immune checkpoint inhibitors (ICIs) has been shown to improve overall survival in NSCLC patients, but it is associated with higher rates of adverse events and treatment discontinuation. The study aimed to evaluate the predictive capacity of NLR in patients with low PD-L1 expression. <br /><br />The study included 142 patients, with 28 receiving combination therapy and 114 receiving chemotherapy alone. Patients who received combination therapy had significantly better progression-free survival (PFS) and overall survival (OS) compared to those who received monotherapy. In the subgroup of patients with a low NLR, combination therapy resulted in extended PFS and OS. Cox proportional hazards regression analysis showed that combination therapy was an independent predictor for both PFS and OS compared to chemotherapy alone in this subgroup.<br /><br />The findings suggest that NLR can be used as a biomarker to predict survival benefits in advanced NSCLC patients with low PD-L1 expression who are receiving combination therapy with chemotherapy and ICIs. This information can help guide treatment decisions and potentially improve outcomes for these patients. Further research is needed to validate these findings and determine the best treatment strategies for NSCLC patients with different levels of PD-L1 expression and NLR.

Asset Subtitle

Chian-Wei Chen

Meta Tag

Speaker Chian-Wei Chen

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

neutrophil-to-lymphocyte ratio

NLR

overall survival

advanced non-small cell lung cancer

NSCLC

low PD-L1 expression

chemoimmunotherapy

combination therapy

progression-free survival

biomarker